

# Sanjay Phogat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10809384/publications.pdf>

Version: 2024-02-01

42  
papers

5,166  
citations

218677

26  
h-index

254184

43  
g-index

44  
all docs

44  
docs citations

44  
times ranked

4642  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
2	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	4.7	33
3	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	8.4	27
4	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
5	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
6	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	5.0	18
7	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
8	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	4.7	19
9	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
10	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
11	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
12	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. <i>PLoS ONE</i> , 2018, 13, e0196397.	2.5	14
13	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	4.7	86
14	In vitro assessment of biological activity and stability of the ALVAC-HIV vaccine. <i>Vaccine</i> , 2018, 36, 5636-5644.	3.8	2
15	HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	3.4	26
16	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	4.0	57
17	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
18	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	4.7	38

#	ARTICLE	IF	CITATIONS
19	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.8	34
20	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	30.7	197
21	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. <i>Journal of Virology</i> , 2016, 90, 4133-4149.	3.4	22
22	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	3.4	40
23	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42
24	Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8525-8539.	3.4	35
25	The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys. <i>Journal of Virology</i> , 2014, 88, 1809-1814.	3.4	62
26	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65
27	HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A34.	1.1	17
28	Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2013, 288, 9815-9825.	3.4	28
29	Identification of an HIV-1 Clade A Envelope That Exhibits Broad Antigenicity and Neutralization Sensitivity and Elicits Antibodies Targeting Three Distinct Epitopes. <i>Journal of Virology</i> , 2013, 87, 5372-5383.	3.4	59
30	Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. <i>Virology</i> , 2012, 426, 34-41.	2.4	28
31	Broad neutralization coverage of HIV by multiple highly potent antibodies. <i>Nature</i> , 2011, 477, 466-470.	27.8	1,397
32	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	3.4	393
33	A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. <i>Virology</i> , 2011, 418, 123-132.	2.4	17
34	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2011, 85, 2524-2535.	3.4	46
35	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	27.8	794
36	Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. <i>Journal of Virology</i> , 2011, 85, 4578-4585.	3.4	43

#	ARTICLE	IF	CITATIONS
37	Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1. <i>Journal of Virology</i> , 2010, 84, 8098-8110.	3.4	209
38	Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. <i>Journal of Virology</i> , 2009, 83, 1045-1059.	3.4	238
39	The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. <i>Nature Reviews Microbiology</i> , 2008, 6, 143-155.	28.6	298
40	Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2706-2711.	7.1	278
41	Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. <i>Journal of Immunological Methods</i> , 2003, 283, 17-25.	1.4	75
42	A four-element based transposon system for allele specific tagging in plantsâ€”Theoretical considerations. <i>Journal of Biosciences</i> , 2000, 25, 57-63.	1.1	4